Menu
Washingtoner
  • Home
  • Business
  • Real Estate
  • Technology
  • Home
  • Health
  • Self Storage
  • Pets
  • Security
Washingtoner

Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
Washingtoner/10175938

Trending...
  • InventHelp Inventor Develops New Accessory for Fishermen (TGR-242)
  • Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
  • Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. ("Kubota Vision"), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride ("emixustat") in patients with macular atrophy secondary to Stargardt disease.

The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 clinical study in which subjects were randomly assigned to emixustat 10 mg or placebo (2:1 ratio) once daily for 24 months. The target total number of subjects was 162; however, due to high interest in the study, a total of 194 subjects were enrolled in this study across 29 sites in 11 countries worldwide. The last patient has completed the study. The primary objective of this study is to determine if emixustat reduces the rate of macular atrophy progression, in comparison to placebo, in subjects with Stargardt disease. Secondary objectives include assessing changes in visual function parameters such as BCVA (best-corrected visual acuity) letter score and reading speed. The database of this study will be locked in the third quarter 2022.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, "Despite Stargardt being a rare disease, we were able to enroll more patients than originally planned and feel grateful that the patients trusted our drug with great expectation and continued taking the drug for two years during the pandemic. We would like to sincerely thank all of the participants and their families for their cooperation and are very pleased that the long-term, large-scale clinical trial has been successfully completed. We are also looking forward to receiving the results of the trial in the coming months."

The FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) granted orphan drug designation to emixustat for the treatment of Stargardt disease. (See January 5, 2017 press release titled "Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease" and June 9, 2019 press release titled "Acucela Receives Orphan Designation from the EMA for Emixustat for the Treatment of Stargardt Disease")

More on Washingtoner
  • The Human Resilience Project Welcomes Laura Lynn van Mierlo as Research Associate; Promotes Lisa Courtnadge to Research Specialist
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
  • Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame

About Stargardt Disease

Stargardt disease is a rare, genetically inherited disease that directly affects the retina of the eye, often resulting in the slow progression of vision loss in children. It may also be referred to as Stargardt macular dystrophy or juvenile macular degeneration and affects approximately 1 in 8,000 - 10,000 individuals worldwide.*1 The most common form of the disease is caused by a genetic mutation of the ABCA4 gene leading to the accumulation of toxic vitamin A byproducts (primarily A2E) in the retina, which results in the gradual deterioration of photoreceptors and vision. Symptoms of Stargardt disease typically appear during childhood or adolescence, but in some cases difficulty with eyesight and vision loss may not be identified until later in life.

Stargardt disease affects less than 150,000 patients in total in the U.S., Europe and Japan where it is recognized as an orphan disease. Currently, there are no known therapies that slow the advance of the disease, and it is recognized as a serious unmet medical need.

*1 Facts About Stargardt Disease, National Eye Institute. https://nei.nih.gov/health/stargardt/star_facts, accessed on 14 September 2018.

About Emixustat Hydrochloride

Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process. Slowing the visual cycle reduces the availability of vitamin A derivatives (11-cis- and all-trans-retinal) to form precursors of toxic A2E and related compounds. In addition, reducing the availability of 11-cis-retinal decreases retinal metabolic demands under dark conditions. Emixustat when delivered orally was found to be generally well tolerated in human clinical studies with delayed dark adaptation being the most common adverse event. Kubota Vision is exploring emixustat's potential to stop or slow the progression of vision loss in patients diagnosed with Stargardt disease in an ongoing clinical study.

More on Washingtoner
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
  • Spokane: Flags Lowered for Justice Owens
  • Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
  • Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements: https://www.kubotaholdings.co.jp/en/1/index.html

"Kubota Vision", the Kubota Vision logo and "Kubota" are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Contacts

Media and Investor Relations Contact:

Mikio Fukai
Corporate Planning Division
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • PNNL's Grid Storage Launchpad honored with 2025 BCI Innovation Award
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
  • New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
  • "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • IGT PlaySports Introduces World-Class Retail Sports Betting to Silver Reef Casino Resort
  • Events by Dubsdread Expands Services to The Venue at Lake Lily
  • London Gala Emphasizes Trade, FDI and Ongoing Cooperation
  • Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
  • Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
  • Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
_catLbl0 _catLbl1

Popular on Washingtoner

  • 11th annual Florida Blueberry Festival April 26 & 27, 2025 - 142
  • HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies - 122
  • People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative - 114
  • Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet - 111
  • American Mensa Welcomes 7-Year-Old Savannah Boy - 110
  • PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth - 109
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT
  • Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
  • S2C and Andes Technology Announce FPGA-Based Prototyping Partnership to Accelerate Advanced RISC-V SoC Development
  • The Great Junk Hunt Returns to Puyallup – A Vintage Shopping Experience Like No Other!

Similar on Washingtoner

  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Beaches and Big Cities Remain the Top Travel Destination for American Summer Travelers
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • Space Resources Company Interlune Unveils Full-Scale Prototype of Excavator for Harvesting Helium-3 from the Moon
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute